I-Mab Shareholders Approve Name Change and Amended Articles of Association

I-Mab, a biopharmaceutical company, held an extraordinary general meeting (EGM) on October 24, 2025, where shareholders approved two key proposals. First, the shareholders approved the change of the company's English name from 'I-Mab' to 'NovaBridge Biosciences' and the dual foreign name from '天境生物' to '新桥生物'. This change will be effective upon the issuance of the certificate of incorporation on change of name by the Registrar of Companies in the Cayman Islands. Second, the shareholders approved the adoption of the seventh amended and restated memorandum and articles of association, which will replace the current sixth amended and restated version. The meeting saw a quorum of approximately 34% of the total outstanding shares, with the proposals receiving overwhelming support from the shareholders.